BiotechTube

DISC-3405

Phase 2Recruiting
0 watching 0 views this week⚡ Active
47
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Polycythemia Vera (PV)

Conditions

Polycythemia Vera (PV)

Trial Timeline

Aug 12, 2025 → Feb 1, 2029

NCT ID
NCT06985147

About DISC-3405

DISC-3405 is a phase 2 stage product being developed by Disc Medicine for Polycythemia Vera (PV). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06985147. Target conditions include Polycythemia Vera (PV).

Hype Score Breakdown

Clinical
17
Activity
12
Company
5
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT07187973Phase 1Recruiting
NCT06985147Phase 2Recruiting

Competing Products

20 competing products in Polycythemia Vera (PV)

See all competitors
ProductCompanyStageHype Score
Sapablursen + PlaceboOno PharmaceuticalPhase 3
77
Ruxolitinib + AbemaciclibEli LillyPhase 1
33
BomedemstatMerckPhase 2
52
Ruxolitinib + Hydroxycarbamide + Interferon-AlphaNovartisPhase 3
77
ruxolitinib tabletsNovartisPhase 3
77
RuxolitinibNovartisPre-clinical
23
RuxolitinibNovartisPhase 3
77
Ruxolitinib + BATNovartisPhase 2
52
HydroxyureaNovartisApproved
85
Best Available Therapy + RuxolitinibNovartisPhase 3
77
Smac Mimetic LCL161NovartisPhase 2
52
PEGASYS + AspirinRochePhase 2
52
RG7388 + PegasysRochePhase 1
33
IdasanutlinRochePhase 2
52
PEGASYS + Hydroxyurea + AspirinRochePhase 3
77
Ropeginterferon alfa-2bPharmaEssentiaPhase 2
51
Pegylated-Proline-Interferon alpha-2b in a Pre-filled PenPharmaEssentiaPhase 3
76
Pegylated-Proline-interferon alpha-2b + Best available therapy (BAT)PharmaEssentiaPhase 3
76
Ropeginterferon alfa-2bPharmaEssentiaApproved
84
P1101 + Low-dose aspirinPharmaEssentiaPhase 2
51

Other Products from Disc Medicine

Placebo + DISC-1459Phase 3
72
DISC-1459 + DISC-1459Phase 2/3
60
DISC-0974 + PlaceboPhase 2
47
DISC-1459 + DISC-1459 + PlaceboPhase 2
47
DISC-0974Phase 1/2
36